Table 7.
Outcome*
| Year | Complete clinical recovery | Residual deficits | Complete radiological recovery | Residual radiological findings | Deaths | Mean follow-up (months) |
|---|---|---|---|---|---|---|
| 2017 | 24 (80%) | Tetraspasticity (1), hearing loss (1), seizures (1), memory and attention deficit (1), hemiparesis (1) | 27 (90%) | White matter lesions (2), brain edema (1) | 2 (6.5%) | 21.4 |
| 2018 | 25 (83%) | Seizure (3), hemiparesis (1), spasticity (1), ataxia (1), aphasia (1), hearing loss (1), memory deficit (1), peripheral neuropathy (1) | 29 (97%) | Gliosis and persistent meningeal impregnation (1) | None | 23.7 |
| 2019 | 22 (88%) | Hemiparesis (1), speech disorders (1), hearing loss (1) | 24 (96%) | Gliosis (1) | None | 24.3 |
| 2020 | 15 (88%) | Hemiparesis (1), tetraparesis (1) | 17 (100%) | None | None | 16.1 |
| 2021 | 18 (78%) | Hemiparesis (1), seizures (2), hemianopsia (1), aphasia (1), dehydration (1) | 19 (82%) | Cerebritis (1), meningeal impregnation (1), ischemia (1), bone gap (1) | 1 (4%) | 12.5 |
| 2022 | 53 (91%) | Facial paresis (1), peripheral neuropathy (1), sequelae of infected of cranioplasty (1) | 52 (89%) | Meningeal impregnation (4), residual empyema (2) | 2 (3.5%) | 7.2 |
| 2023 | 59 (83%) | Hemiparesis (3), raised ICP signs (1), cranial nerve palsy (1), behavioral problems (1), speech problems (1) | 46 (64%) | Meningeal impregnation (3), residual empyema (8), sinus thrombosis (2) | 2 (2.8%) | 2.3 |
| Overall | 216 (85%) | / | 214 (84%) | / | 7 (2.7%) | 12.4 |
*Still ongoing treatment in 10 cases (all belonging to the 2023 period)